Search

Merck & Co Inc.

Slēgts

SektorsVeselības aprūpe

147.08 1.5

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

143.4

Max

144.94

Galvenie mērījumi

By Trading Economics

Ienākumi

2.9B

-1.3B

Pārdošana

321M

17B

P/E

Sektora vidējais

115.88

56.432

EPS

-0.13

Dividenžu ienesīgums

2.31

Peļņas marža

-8.051

Darbinieki

73,000

EBITDA

3.4B

1.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+11.61% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.31%

2.27%

Nākamie ieņēmumi

2026. g. 29. okt.

Nākamais dividenžu datums

2026. g. 7. okt.

Nākamais Ex dividenžu datums

2026. g. 14. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

50B

357B

Iepriekšējā atvēršanas cena

145.58

Iepriekšējā slēgšanas cena

147.08

Ziņu noskaņojums

By Acuity

37%

63%

75 / 339 Rangs Healthcare

Merck & Co Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. sept. 23:51 UTC

Merck & Co Inc is advancing in after-market trading, supported by positive U.S. retail sales data, despite ongoing concerns over TIC flows and Treasury yields.

2026. g. 15. sept. 23:01 UTC

Merck & Co Inc shares are lower in after-market hours. Broader market sentiment is impacted by a significant decline in the New York Empire State Manufacturing Index.

2026. g. 14. sept. 23:06 UTC

Merck & Co Inc shares rose in after-market trading following Monday's close, despite earlier declines and no specific news to explain the movement.

2026. g. 11. sept. 19:36 UTC

Merck & Co Inc shares are declining amid broader market trends following inflation data that heightened interest rate hike speculation. No specific company news was identified.

2026. g. 10. sept. 20:07 UTC

News

Merck & Co Inc shares are lower today despite HSBC raising its price target to $172 and noting insider buying activity.

2026. g. 9. sept. 19:36 UTC

News

Merck & Co. shares are lower after a court upheld Medicare's drug-price negotiations, raising concerns about future prescription drug spending.

2026. g. 8. sept. 23:06 UTC

News

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

2026. g. 4. sept. 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

2026. g. 3. sept. 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2026. g. 2. sept. 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

2026. g. 1. sept. 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

2026. g. 31. aug. 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

2026. g. 28. aug. 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

2026. g. 27. aug. 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

2026. g. 26. aug. 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

2026. g. 25. aug. 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

2026. g. 24. aug. 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

2026. g. 21. aug. 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

2026. g. 20. aug. 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

2026. g. 19. aug. 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

2026. g. 17. aug. 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

2026. g. 15. aug. 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

2026. g. 14. aug. 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

2026. g. 13. aug. 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

2026. g. 12. aug. 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

2026. g. 11. aug. 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

2026. g. 10. aug. 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

2026. g. 7. aug. 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

2026. g. 6. aug. 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

2026. g. 5. aug. 19:43 UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

Salīdzinājums

Cenas izmaiņa

Merck & Co Inc. Prognoze

Cenas mērķis

By TipRanks

11.61% augšup

Prognoze 12 mēnešiem

Vidējais 160.489 USD  11.61%

Augstākais 180 USD

Zemākais 105 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merck & Co Inc.  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

14

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

75 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat